Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sensorion
  6. News
  7. Summary
    ALSEN   FR0012596468

SENSORION

(ALSEN)
  Report
Real-time Euronext Paris  -  06:00 2022-12-09 am EST
0.3800 EUR   -3.80%
11/30Sensorion Wins US FDA's Orphan Drug Tag for Hearing Loss Gene Therapy
MT
11/07Sensorion's Gene Therapy for Hearing Loss Wins Rare Pediatric Disease Tag in US
MT
11/07Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to Otof-Gt for the Treatment of Otoferlin Gene-Mediated Hearing Loss
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

06/07/2022 | 01:30am EST

Sensorion announced that the initiation of a Proof of Concept (POC) clinical trial of SENS-401 (Arazasetron) in patients scheduled for cochlear implantation has been approved by regulatory authorities in France. Approval has been granted to launch a Phase 2a trial with SENS-401 for hearing preservation in patients who, due to having moderately severe to profound hearing impairment, are scheduled for cochlear implantation. The trial will be a multicenter, randomized, controlled, open-label trial to evaluate the presence of SENS-401 in the cochlea (perilymph) after 7 days of twice-daily oral administration in adult participants prior to cochlear implantation.

Patients will receive SENS-401 for 49 days. The trial will also assess a number of secondary outcome measures, including the change of hearing threshold from baseline to the end of the study in the implanted ear at several frequencies. As previously announced, first patient enrolment is anticipated by mid-2022.

At the beginning of 2021, Sensorion released positive preclinical data demonstrating that the combination of its SENS-401 molecule alongside a cochlear implant helped reduce loss of residual hearing at a frequency located beyond the electrode array. Preservation of ‘natural' hearing is particularly important in speech recognition. Preclinical studies were undertaken in collaboration with the global leader in implantable hearing, Cochlear Ltd.


ę S&P Capital IQ 2022
All news about SENSORION
11/30Sensorion Wins US FDA's Orphan Drug Tag for Hearing Loss Gene Therapy
MT
11/07Sensorion's Gene Therapy for Hearing Loss Wins Rare Pediatric Disease Tag in US
MT
11/07Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to Otof-Gt for the..
CI
10/24Sensorion Wins Regulatory Nod to Launch Mid-Stage Study of Cisplatin-Induced Hearing Lo..
MT
10/24Sensorion SA Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical ..
CI
09/22Sensorion SA Reports Earnings Results for the Half Year Ended June 30, 2022
CI
09/22SENSORION : 1st-half-year results
CO
09/14Sensorion Enrolls First Patient in SENS-401 Clinical Trial
MT
09/14Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-4..
CI
09/12Sensorion Receives Positive Opinion in Europe on Orphan Drug Designation for Hearing Lo..
MT
More news
Financials
Sales 2022 5,53 M 5,84 M 5,84 M
Net income 2022 -21,4 M -22,6 M -22,6 M
Net Debt 2022 20,1 M 21,2 M 21,2 M
P/E ratio 2022 -1,46x
Yield 2022 -
Capitalization 31,6 M 33,3 M 33,3 M
EV / Sales 2022 9,33x
EV / Sales 2023 12,5x
Nbr of Employees 38
Free-Float 50,7%
Chart SENSORION
Duration : Period :
Sensorion Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SENSORION
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,40 €
Average target price 2,80 €
Spread / Average Target 609%
EPS Revisions
Managers and Directors
Nawal Ouzren Chief Executive Officer & Director
Scott D. Myers Chairman
GÚraldine Honnet Chief Medical Officer
Eric Forquenot de la Fortelle Independent Director
Julien Miara Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SENSORION-79.49%33
MODERNA, INC.-29.52%70 958
IQVIA HOLDINGS INC.-25.42%39 082
LONZA GROUP AG-39.99%36 246
ALNYLAM PHARMACEUTICALS, INC.36.41%29 282
SEAGEN INC.-18.99%23 253